Pronto disponible para inscripción
This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

ALPINE - Clinical Trial

¿Cuál es el Propósito de este estudio?

In this study, patients will first receive either the study drug or a placebo for 24 weeks. After that, everyone in the study will receive the real drug for 28 weeks. The whole study will last about 60 weeks. Each person will need to come to the clinic nine times during the study. All visits will take place at the South Durham Clinic.

¿Cuál es la Condición que se está estudiando?

Lichen Planopilaris (LPP)

¿Quién puede participar en el Estudio?

People can join this study if they are at least 18 years old. They must have active lichen planopilaris that is rated as moderate or severe. They also need to have a biopsy that shows they have this condition, and the biopsy can be up to five years old. Their weight must be more than 40 kilograms and less than 130 kilograms, and their body mass index must be lower than 45.

Grupo etario
Adultos

¿Qué Implica?

The ALPINE study wants to find out if a medicine called brepocitinib can help control a condition called lichen planopilaris. The medicine is a pill that people take once each day. The study will also compare how well the medicine works when compared to a placebo, which is a pill that has no medicine in it.

Detalles del Estudio

Título Completo
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Lichen Planopilaris
Investigador Principal
Anne Louise Marano, MD
Especialista en dermatología
Número de Protocolo
IRB: PRO00119603
Fase
Phase II/III
Estado de inscripción
Pronto disponible para inscripción
Apoye la investigación de Duke Health o rinda homenaje a un ser querido con un regalo conmemorativo.
Contribuya a Duke Health